Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response.
Sophie E WillisClaudia WinklerMartine P RoudierTarrion BairdPaola Marco-CasanovaEmma V JonesPhilip RoweJaime Rodriguez-CanalesHelen K AngellFelicia S L NgPaul M WaringDarren HodgsonJonathan A LedermannJohanne I WeberpalsEmma DeanElizabeth A HarringtonJ Carl BarrettAndrew J PierceElisabetta LeoGemma N JonesPublished in: British journal of cancer (2021)
We provide clinical evidence supporting the role of SLFN11 as a DDA therapy selection biomarker in SCLC and highlight the need for further clinical investigation into SLFN11 as a PARP inhibitor predictive biomarker.